Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Latest filing published 06 Apr 2026 for Altimmune, Inc., €27k. Read the official filing
Filing timeline
BuySaleJohn Gill
Insider track record
Disclosed buys
2
Disclosed sells
1
Signal history
Closed purchases
Market purchases
2
Positive at T+90
0%
Median T+90
-13.7%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -8.9%Entry US$3.38 · Close at T+90 US$3.08
- -18.6%Entry US$3.98 · Close at T+90 US$3.24
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
John Gill: trading record in brief
John Gill appears in our data through filings on Altimmune, Inc. shares, published by SEC (Form 4). We count 4 filings; the first trade dates from 6 January 2022 and the latest from 6 April 2026.
The open-market side counts 2 purchases for €71k alongside 1 sale for €39k. On balance, insiders were net buyers of €31k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2026, the count stands at 1 purchase and no sales.
The latest filing, published on 6 April 2026, reports an open-market purchase of €27k in Altimmune, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to John Gill
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
4 of 4 declarations
